ArticleBMC cancer2024

Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis.

Mingxia Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.